Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 516

Related Citations for PubMed (Select 23573206)

1.

Genetic loci associated with Alzheimer's disease and cerebrospinal fluid biomarkers in a Finnish case-control cohort.

Elias-Sonnenschein LS, Helisalmi S, Natunen T, Hall A, Paajanen T, Herukka SK, Laitinen M, Remes AM, Koivisto AM, Mattila KM, Lehtimäki T, Verhey FR, Visser PJ, Soininen H, Hiltunen M.

PLoS One. 2013;8(4):e59676. doi: 10.1371/journal.pone.0059676. Epub 2013 Apr 3.

2.

Genome-wide association reveals genetic effects on human Aβ42 and τ protein levels in cerebrospinal fluids: a case control study.

Han MR, Schellenberg GD, Wang LS; Alzheimer's Disease Neuroimaging Initiative.

BMC Neurol. 2010 Oct 8;10:90. doi: 10.1186/1471-2377-10-90.

3.

Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.

Lautner R, Palmqvist S, Mattsson N, Andreasson U, Wallin A, Pålsson E, Jakobsson J, Herukka SK, Owenius R, Olsson B, Hampel H, Rujescu D, Ewers M, Landén M, Minthon L, Blennow K, Zetterberg H, Hansson O; Alzheimer’s Disease Neuroimaging Initiative.

JAMA Psychiatry. 2014 Oct;71(10):1183-91. doi: 10.1001/jamapsychiatry.2014.1060.

PMID:
25162367
4.

Genome-wide association study of CSF biomarkers Abeta1-42, t-tau, and p-tau181p in the ADNI cohort.

Kim S, Swaminathan S, Shen L, Risacher SL, Nho K, Foroud T, Shaw LM, Trojanowski JQ, Potkin SG, Huentelman MJ, Craig DW, DeChairo BM, Aisen PS, Petersen RC, Weiner MW, Saykin AJ; Alzheimer's Disease Neuroimaging Initiative.

Neurology. 2011 Jan 4;76(1):69-79. doi: 10.1212/WNL.0b013e318204a397. Epub 2010 Dec 1.

5.

Impact of SORL1 single nucleotide polymorphisms on Alzheimer's disease cerebrospinal fluid markers.

Alexopoulos P, Guo LH, Kratzer M, Westerteicher C, Kurz A, Perneczky R.

Dement Geriatr Cogn Disord. 2011;32(3):164-70. doi: 10.1159/000332017. Epub 2011 Oct 13.

6.

Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype.

Blom ES, Giedraitis V, Zetterberg H, Fukumoto H, Blennow K, Hyman BT, Irizarry MC, Wahlund LO, Lannfelt L, Ingelsson M.

Dement Geriatr Cogn Disord. 2009;27(5):458-64. doi: 10.1159/000216841. Epub 2009 May 7.

PMID:
19420940
7.

Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.

Sunderland T, Mirza N, Putnam KT, Linker G, Bhupali D, Durham R, Soares H, Kimmel L, Friedman D, Bergeson J, Csako G, Levy JA, Bartko JJ, Cohen RM.

Biol Psychiatry. 2004 Nov 1;56(9):670-6.

PMID:
15522251
8.

Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: a longitudinal MRI study.

Tosun D, Schuff N, Truran-Sacrey D, Shaw LM, Trojanowski JQ, Aisen P, Peterson R, Weiner MW; Alzheimer's Disease Neuroimaging Initiative.

Neurobiol Aging. 2010 Aug;31(8):1340-54. doi: 10.1016/j.neurobiolaging.2010.04.030. Epub 2010 Jun 8.

9.

CSF beta-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele.

Smach MA, Charfeddine B, Lammouchi T, Harrabi I, Ben Othman L, Dridi H, Bennamou S, Limem K.

Neurosci Lett. 2008 Aug 1;440(2):145-9. doi: 10.1016/j.neulet.2008.05.076. Epub 2008 May 24.

PMID:
18555606
10.

SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer's disease.

Cruchaga C, Kauwe JS, Mayo K, Spiegel N, Bertelsen S, Nowotny P, Shah AR, Abraham R, Hollingworth P, Harold D, Owen MM, Williams J, Lovestone S, Peskind ER, Li G, Leverenz JB, Galasko D; Alzheimer's Disease Neuroimaging Initiative, Morris JC, Fagan AM, Holtzman DM, Goate AM.

PLoS Genet. 2010 Sep 16;6(9):e1001101. doi: 10.1371/journal.pgen.1001101.

11.

Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls.

Martínez-Morillo E, Hansson O, Atagi Y, Bu G, Minthon L, Diamandis EP, Nielsen HM.

Acta Neuropathol. 2014 May;127(5):633-43. doi: 10.1007/s00401-014-1266-2. Epub 2014 Mar 15.

PMID:
24633805
12.

Fine mapping of genetic variants in BIN1, CLU, CR1 and PICALM for association with cerebrospinal fluid biomarkers for Alzheimer's disease.

Kauwe JS, Cruchaga C, Karch CM, Sadler B, Lee M, Mayo K, Latu W, Su'a M, Fagan AM, Holtzman DM, Morris JC; Alzheimer's Disease Neuroimaging Initiative, Goate AM.

PLoS One. 2011 Feb 9;6(2):e15918. doi: 10.1371/journal.pone.0015918.

13.

Apolipoprotein E epsilon4 does not modulate amyloid-β-associated neurodegeneration in preclinical Alzheimer disease.

Desikan RS, McEvoy LK, Holland D, Thompson WK, Brewer JB, Aisen PS, Andreassen OA, Hyman BT, Sperling RA, Dale AM; Alzheimer's Disease Neuroimaging Initiative.

AJNR Am J Neuroradiol. 2013 Mar;34(3):505-10. doi: 10.3174/ajnr.A3267. Epub 2012 Sep 13.

14.

Amyloid-β 1-42 levels are modified by apolipoprotein E ε4 in Creutzfeldt-Jakob disease in a similar manner as in Alzheimer's disease.

Varges D, Jung K, Gawinecka J, Heinemann U, Schmitz M, von Ahsen N, Krasnianski A, Armstrong VW, Zerr I.

J Alzheimers Dis. 2011;23(4):717-26. doi: 10.3233/JAD-2010-101527.

PMID:
21157024
15.

CSF biomarkers in Alzheimer's disease and controls: associations with APOE genotype are modified by age.

Kester MI, Blankenstein MA, Bouwman FH, van Elk EJ, Scheltens P, van der Flier WM.

J Alzheimers Dis. 2009;16(3):601-7. doi: 10.3233/JAD-2009-0999.

PMID:
19276554
16.

The effects of normal aging and ApoE genotype on the levels of CSF biomarkers for Alzheimer's disease.

Glodzik-Sobanska L, Pirraglia E, Brys M, de Santi S, Mosconi L, Rich KE, Switalski R, Saint Louis L, Sadowski MJ, Martiniuk F, Mehta P, Pratico D, Zinkowski RP, Blennow K, de Leon MJ.

Neurobiol Aging. 2009 May;30(5):672-81. Epub 2007 Oct 24.

17.

No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease.

Engelborghs S, Sleegers K, Cras P, Brouwers N, Serneels S, De Leenheir E, Martin JJ, Vanmechelen E, Van Broeckhoven C, De Deyn PP.

Brain. 2007 Sep;130(Pt 9):2320-6. Epub 2007 Jun 22.

18.

Association of complement factor H Y402H gene polymorphism with Alzheimer's disease.

Zetterberg M, Landgren S, Andersson ME, Palmér MS, Gustafson DR, Skoog I, Minthon L, Thelle DS, Wallin A, Bogdanovic N, Andreasen N, Blennow K, Zetterberg H.

Am J Med Genet B Neuropsychiatr Genet. 2008 Sep 5;147B(6):720-6. doi: 10.1002/ajmg.b.30668.

PMID:
18163432
19.

Association of the RAGE G82S polymorphism with Alzheimer's disease.

Daborg J, von Otter M, Sjölander A, Nilsson S, Minthon L, Gustafson DR, Skoog I, Blennow K, Zetterberg H.

J Neural Transm. 2010 Jul;117(7):861-7. doi: 10.1007/s00702-010-0437-0. Epub 2010 Jun 22.

20.

Stage-dependent agreement between cerebrospinal fluid proteins and FDG-PET findings in Alzheimer's disease.

Yakushev I, Muller MJ, Buchholz HG, Lang U, Rossmann H, Hampel H, Schreckenberger M, Fellgiebel A.

Curr Alzheimer Res. 2012 Feb;9(2):241-7.

PMID:
22044023
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk